Intravesical application of targeting EGFR 213Bi α-particle emitter containing immunoconjugate showed promising results in early tumor stages using mouse in situ human bladder cancer xenografts (Pfost et al., 2009; Fazel et al., 2015). The gene discussed is EGFR; the disease is urinary bladder carcinoma.